Compare Adaptive Biotechnologies Corp (ADPT) vs Eni SpA (E) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Eni SpA — how do they compare? Adaptive Biotechnologies Corp trades at $19.93 (market cap $3.33B), while Eni SpA trades at $48.39 (market cap $67.72B). The key difference: Eni SpA is far larger — about 20.3× Adaptive Biotechnologies Corp's market cap, and Eni SpA pays a 5.25% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | E | |
|---|---|---|
Market Cap | $3.33B | $67.72B |
Sector | Health | Energy |
52-Week High | $22.37 | $57.61 |
52-Week Low | $10.24 | $32.93 |
Enterprise Value | $3.19B | $86.63B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Eni (E) trades at $47.47, up 1.28% with a bearish technical signal despite recent earnings beats. The company shows stable cash flow generation with $13.33B operating cash flow in 2025 and maintains a reasonable valuation with P/E of 20.51 and P/S of 0.75. Recent strategic moves include lithium investments in Chile and fusion energy partnerships, signaling diversification beyond traditional energy operations.
While analyst consensus leans neutral (61.53% hold), Eni's transition strategy and global expansion present long-term opportunities. Key risks include declining revenue trends from $132.5B in 2022 to $82.15B in 2025 and competitive pressures in the energy sector. The stock offers value characteristics with dividend income potential amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
